LigoCyte

Acquired by Takeda
Developing innovative vaccines for the prevention of gastrointestinal diseases.

Investment Team

Sector

Life Sciences

Category

Therapeutics

Location

Bozeman, MT

Initial Investment

2008
Developing innovative vaccines for the prevention of gastrointestinal diseases.

LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.